Nordic Summer School of Cancer Epidemiology , phase III

(in alphabetical order according to surname of the first presenting author) CIP2A IS A MARKER OF REDUCED SURVIVAL IN SEROUS OVARIAN CANCER PATIENTS Camilla Böckelman, Heini Lassus, Annabrita Hemmes, Arto Leminen, Jukka Westermarck, Caj Haglund, Ralf Bützow, Ari Ristimäki Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland. Department of Pathology, HUSLAB and Haartman Institute, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. Department of Surgery, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. Department of Obstetrics and Gynecology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland. Department of Pathology, University of Turku, Turku, Finland. Department of Pathology, Institute of Diagnostics, University of Oulu and Oulu University Hospital, Oulu, Finland. Cancerous inhibitor of PP2A (CIP2A) is a recently identified oncoprotein, but its role in ovarian cancer is not known. We analyzed CIP2A protein expression in 562 consecutive serous ovarian cancer patients, of which 524 were scored successfully and analyzed for presence of CIP2A immunopositivity using tissue microarrays. The association of CIP2A expression with survival was evaluated according to the Kaplan-Meier method. We found strong CIP2A positive immunostaining in 212 (40.4%) specimens, 222 (42.4%) were weakly positive, while the rest (n = 90, 17.2%) were immunonegative for CIP2A protein. Our results demonstrate that CIP2A immunopositivity is a marker of reduced overall survival in ovarian cancer patients (P < 0.0001). In addition, positive CIP2A expression was significantly more frequent in specimens with high grade (P < 0.0001), advanced stage (P = 0.0005), aberrant p53 immunoreactivity (P < 0.0001), high proliferation index (P < 0.0001), and aneuploidy (P = 0.001). Interestingly, in subgroups of patients with favorable clinical factors (i.e. low stage and optimal debulking surgery) CIP2A expression was strongly associated with reduced survival (P < 0.0001 for both parameters). This shows that CIP2A could be used to predict biological behavior in the group of patients with otherwise favorable prognosis. In conclusion, our results show that CIP2A protein expression is a novel marker of reduced survival in patients with serous ovarian carcinoma. Furthermore, these results suggest that CIP2A characterizes the aggressive type of this disease even within subgroups with initially favorable prognosis. Trends in incidence of malignant melanoma and non melanoma skin cancer in Denmark 1943-2007. A descriptive study Astrid Knudsen* and Kim K. B. Clemmensen* *The Danish Cancer Registry Background In 2007 Danish Cancer Society launched an ongoing sun protection campaign. In connection with this campaign we plan to further investigate recreational UVexposure. As an initial introduction to this subject, we here want to describe how the incidence of cancers related to UV-exposure (non melanoma skin cancer (NMSC) and malignant melanoma (MM)) has developed in Denmark since 1943. Multiple factors influence the incidence trends i.e. changes in intermittent UV-exposure patterns from vacations, sunbed use and intentional tanning. Material The Danish Cancer Registry is a population-based registry containing data on the incidence of cancer throughout Denmark since 1943. Reporting of cancer was made mandatory by administrative order in 1987. Details of individual cases of cancer are available according to the 7th revision of the International Classification of Diseases (ICD) for all years, and according to the ICD-O since 1978. A core data set is kept on each individual which includes date of birth, sex, date of cancer diagnosis, method of verification, date of death and cause of death. Methods Data from The Danish Cancer Registry 1943-2007. SAS-programmes: Niels Christensen, The Danish Cancer Society. The incidence rates were age-standardized to WSP (world). MM data: the ICD-10 codes C430-C439. NMSC data: the ICD-10 codes C440-C449, C60. Results Time trends: Overall the incidence of MM for both women and men in Denmark has increased steeply since 1943. NMSC incidence in Denmark has increased since 1960 and especially since 1975. Age incidence: The incidence of MM increases with age, but the disease occurs among young individuals from 15 years of age. The NMSC incidence increases steadily with age, however the disease is rare before the age of 40 years. Conclusions The incidence of both MM and SC has increased in Denmark. One factor which might contribute to the rise in incidence of these cancers is increased intermittent UV exposure during vacations. This we plan to address in further investigation of recreational UV-exposure looking at travelling patterns in the Danish population. THE ASSOCIATION BETWEEN CANCER TREATMENT, REHABILITATION AND PERMANENT WORK MARKET WITHDRAWAL IN DANISH BREAST CANCER SURVIVORS.